diff options
| author | muqiuhan <[email protected]> | 2025-12-29 13:29:56 +0000 |
|---|---|---|
| committer | muqiuhan <[email protected]> | 2025-12-29 13:29:56 +0000 |
| commit | 8bb6d75fed65b1d5371ace05f5d0956df915956d (patch) | |
| tree | 1b749197c64bd773db7bccc554a58bf7752c202e /2025/11/29 | |
| parent | ce95ec2442e0cdd67710ec3cdb0a8b03849524fe (diff) | |
| download | blog-8bb6d75fed65b1d5371ace05f5d0956df915956d.tar.gz | |
deploy: 125862a284943979eed046927483686b770da9ff
Diffstat (limited to '2025/11/29')
| -rw-r--r-- | 2025/11/29/FDA-仿制药流程/index.html | 309 |
1 files changed, 309 insertions, 0 deletions
diff --git a/2025/11/29/FDA-仿制药流程/index.html b/2025/11/29/FDA-仿制药流程/index.html new file mode 100644 index 00000000..8fcc012c --- /dev/null +++ b/2025/11/29/FDA-仿制药流程/index.html @@ -0,0 +1,309 @@ +<!DOCTYPE html> +<html lang="en"> + <head> + <meta charset="UTF-8"> +<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0"> +<meta http-equiv="X-UA-Compatible" content="ie=edge"> + + <meta name="author" content="韩暮秋"> + + + <meta name="subtitle" content="暮秋小屋"> + + + <meta name="description" content="这里是暮秋小屋,思念和灵感的寄存处"> + + + <meta name="keywords" content="韩暮秋,MuqiuHan,'Muqiu Han', 'muqiu han', muqiuhan"> + + + + + <title> + + FDA 仿制药流程 | + 暮秋小屋 + </title> + + + + <link rel="icon" href="/favicon.ico"> + + + <style> + @font-face { + font-family: CarroisSong; + src: url('/fonts/CarroisSong.ttf'); + } + </style> + + + + <!-- stylesheets list from _config.yml --> + + <link rel="stylesheet" href="/css/style.css"> + + + + + + <!-- scripts list from _config.yml --> + + <script + src="/js/menu.js"></script> + + + + + + <script + src="https://polyfill.alicdn.com/polyfill.js?features=es6"></script> + <script + id="MathJax-script" + async + src="https://lf6-cdn-tos.bytecdntp.com/cdn/expire-1-M/mathjax/3.2.0/es5/tex-mml-chtml.js"></script> + + + + + <meta name="generator" content="Hexo 6.3.0"></head> + <body> + <div class="mask-border"> + </div> + + <div class="wrapper"> + + <div class="header"> + <div class="flex-container"> + <div class="header-inner"> + <div class="site-brand-container"> + <a href="/"> + + 暮秋小屋 + + </a> + </div> + <div id="menu-btn" class="menu-btn" onclick="toggleMenu()"> + 菜单 + </div> + <nav class="site-nav"> + <ul class="menu-list"> + + + <li class="menu-item"> + <a href="/"> + 主页 + </a> + </li> + + + + <li class="menu-item"> + <a href="/categories/gallery/"> + 日记本 + </a> + </li> + + + + <li class="menu-item"> + <a href="/tags/Medicine/"> + 医学 + </a> + </li> + + + + <li class="menu-item"> + <a href="/tags/Technique/"> + 计算机/互联网 + </a> + </li> + + + + <li class="menu-item"> + <a href="/tags/Life/"> + 生活 + </a> + </li> + + + + <li class="menu-item"> + <a href="/archives"> + 全部 + </a> + </li> + + + + <li class="menu-item"> + <a href="/about"> + 关于 + </a> + </li> + + + + <li class="menu-item search-btn"> + <a href="#">Search</a> + </li> + + </ul> + </nav> + </div> + </div> +</div> + + <div class="main"> + <div class="flex-container"> + <article id="post"> + + + <div class="post-head"> + <div class="post-info"> + <div class="tag-list"> + + + <span class="post-tag"> + <a href="/tags/Medicine/"> + Medicine + </a> + </span> + + + </div> + <div class="post-title"> + + + FDA 仿制药流程 + + + </div> + <span class="post-date"> + Nov 29, 2025 + </span> + </div> + <div class="post-img"> + + <div class="h-line-primary"></div> + + </div> +</div> + <div class="post-content"> + <p>#药物研发</p> +<p>在FDA监管的药物研发、临床试验和上市流程中,当一个已上市药物(通常指创新药,通过新药申请NDA获得批准)出现一种更低廉的制药方式,但其活性成分的分子式保持完全相同时,这种情况本质上涉及仿制药(generic drug)的开发或工艺优化申请,而非从零开始的全新药物研发。简单来说,不需要重新进行完整的临床试验(即I-III期的大规模人体试验),但必须通过简化的监管路径证明新制药方式生产的药物与原药在质量、安全性和疗效上等效。</p> +<p>首先,理解核心前提:分子式完全相同意味着活性成分(active pharmaceutical ingredient, API)是相同的化学实体,例如从专利保护的原研药转向无专利保护的仿制药生产。这不同于生物制品(如单克隆抗体)的生物类似药,后者可能需要更多比较性临床试验。FDA将此类药物归类为“仿制药”,其审批路径是缩减新药申请(Abbreviated New Drug Application, ANDA),而非完整的NDA。ANDA的目的是避免重复证明已知的安全性和有效性数据,这些数据已在原药的NDA中确立<sup class="footnote-ref"><a href="#fn1" id="fnref1">[1]</a></sup>。</p> +<p>FDA的《仿制药用户费用法案》(GDUFA)和相关指南明确规定,对于相同分子式的药物,新制药方式(如改进的合成路线、晶型优化或更高效的提取工艺)只需证明“生物等效性”(bioequivalence),而非全面临床试验。生物等效性研究通常包括:1)体外溶出测试(in vitro dissolution),评估药物在模拟生理条件下的释放速率;2)人体药代动力学研究(pharmacokinetic studies),在健康志愿者中比较新药与原药的吸收、分布、代谢和排泄曲线(如AUC和Cmax参数的90%置信区间在80%-125%内)。这些研究规模小,通常只需24-36名受试者,持续数周,而非数年<sup class="footnote-ref"><a href="#fn2" id="fnref2">[2]</a></sup>。如果新工艺导致杂质谱或稳定性变化,FDA可能要求额外的数据,如加速稳定性测试或毒性评估,但仍无需重复疗效试验,除非有证据显示潜在差异(如新杂质超过许可阈值)<sup class="footnote-ref"><a href="#fn3" id="fnref3">[3]</a></sup>。</p> +<p>在实际操作中,这一路径大大降低了成本和时间:ANDA审批平均需10-15个月,费用远低于NDA的数亿美元和数年周期。新制药方式的低廉性往往源于规模化生产或工艺创新,但FDA要求申请者提交化学、制造和控制(CMC)信息,证明新工艺符合良好生产规范(cGMP)。例如,阿司匹林或扑热息痛等经典药物,其多种仿制药版本均通过此路径上市,而无需重新验证其止痛或抗炎疗效<sup class="footnote-ref"><a href="#fn4" id="fnref4">[4]</a></sup>。然而,如果新方式涉及重大变更(如从化学合成转为生物合成,尽管分子式相同),FDA可能视其为“混合型”申请,需要桥接研究来确认等效性。</p> +<p>如果生物等效性未能证明(例如,新工艺导致生物利用度差异>20%),申请将被拒,或需额外桥接试验,这可能增加延误和成本。不过上市后监测(post-marketing surveillance)仍适用,包括不良事件报告(FAERS系统),以捕捉任何罕见差异。</p> +<hr class="footnotes-sep"> +<section class="footnotes"> +<ol class="footnotes-list"> +<li id="fn1" class="footnote-item"><p>U.S. Food and Drug Administration. (2023). <em>Frequently Asked Questions about Generic Drugs</em>. Retrieved from <a target="_blank" rel="noopener" href="https://www.fda.gov/drugs/generic-drugs/frequently-asked-questions-about-generic-drugs">https://www.fda.gov/drugs/generic-drugs/frequently-asked-questions-about-generic-drugs</a> <a href="#fnref1" class="footnote-backref">↩︎</a></p> +</li> +<li id="fn2" class="footnote-item"><p>U.S. Food and Drug Administration. (2019). <em>Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA</em>. Guidance for Industry. Retrieved from <a target="_blank" rel="noopener" href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug</a> <a href="#fnref2" class="footnote-backref">↩︎</a></p> +</li> +<li id="fn3" class="footnote-item"><p>U.S. Food and Drug Administration. (2020). <em>Changes to an Approved NDA or ANDA</em>. Guidance for Industry. Retrieved from <a target="_blank" rel="noopener" href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-nda-or-anda">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-nda-or-anda</a> <a href="#fnref3" class="footnote-backref">↩︎</a></p> +</li> +<li id="fn4" class="footnote-item"><p>U.S. Food and Drug Administration. (2023). <em>Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)</em>. Retrieved from <a target="_blank" rel="noopener" href="https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book">https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book</a> <a href="#fnref4" class="footnote-backref">↩︎</a></p> +</li> +</ol> +</section> + +</div> + +<script> + window.onload = detectors(); +</script> + <div class="post-footer"> + <div class="h-line-primary"></div> + <nav class="post-nav"> + <div class="prev-item"> + + <div class="icon arrow-left"></div> + <div class="post-link"> + <a href="/2025/12/02/%E2%80%9C%E7%BC%BA%E9%A1%B5%E2%80%9D-%E5%92%8C-%E2%80%9C%E4%B8%AD%E6%96%AD%E2%80%9D-%E6%9C%AF%E8%AF%AD%E4%B8%8A%E7%9A%84%E5%8C%BA%E5%88%AB/">Prev</a> + </div> + + </div> + <div class="next-item"> + + <div class="icon arrow-right"></div> + <div class="post-link"> + <a href="/2025/11/27/%E4%BA%8C%E3%80%87%E4%BA%8C%E4%BA%94%E5%B9%B4%E5%8D%81%E4%B8%80%E6%9C%88%E4%BA%8C%E5%8D%81%E4%B8%83%E6%97%A5/">Next</a> + </div> + + </div> + </nav> +</div> + + + <div class="post-comment"> + + + + + + + +</div> + + +</article> + </div> + </div> + + <div class="footer"> + <div class="flex-container"> + <div class="footer-text"> + + + 韩暮秋 | + + + 希望路过的人可以添点柴火让这里暖和点 + + </div> + </div> +</div> + + </div> + + + <div class="search-popup"> + <div class="search-popup-overlay"> + </div> + <div class="search-popup-window" > + <div class="search-header"> + <div class="search-input-container"> + <input autocomplete="off" autocapitalize="off" maxlength="80" + placeholder="Search Anything" spellcheck="false" + type="search" class="search-input"> + </div> + <div class="search-close-btn"> + <div class="icon close-btn"></div> + </div> + </div> + <div class="search-result-container"> + </div> + </div> +</div> + +<script> + const searchConfig = { + path : "/search.xml", + top_n_per_article: "1", + unescape : "false", + trigger: "auto", + preload: "false" + } +</script> +<script src="https://cdn.jsdelivr.net/npm/[email protected]/dist/search.js"></script> +<script src="/js/search.js"></script> + + + + </body> +</html> |
